We then performed an assessment of cytokine profiles on tumor samples and found greater expression levels of certain cytokines (IFN gamma) and chemokines (IP-10, MCP-1, MIP-1 beta, and RANTES) in CAR T-cell-treated tumors. This evidence concerns the gene CCL2 and neoplasm.